



Miltenyi Biotec

Selected reference list

Graft engineering

1. Keever-Taylor *et al.* (2012) *Biol. Blood Marrow Transplant.* 18: 690–697.
2. Aversa *et al.* (2005): *J. Clin. Oncol.* 23: 3447–3454.
3. Aversa *et al.* (2008): *Blood Cells Mol. Dis.* 40: 8–12.
4. Ciceri *et al.* (2008) *Blood* 112: 3574–3581.
5. Handgretinger *et al.* (2001) *Bone Marrow Transplant.* 27: 777–783.
6. Devine *et al.* (2011) *Biol. Blood Marrow Transplant.* 17: 1343–1351.
7. Pasquini *et al.* (2012) *J. Clin. Oncol.* 30: 3194–3201.
8. Klyuchnikov *et al.* (2009) *Bone Marrow Transplant.* 43: S158.
9. Cho *et al.* (2007) *Blood* 110: Abstract 1111.
10. Oyekunle *et al.* (2006) *Cytotherapy* 8: 375–380.
11. Larocca *et al.* (2006) *Haematologica* 91: 935–940.
12. Lang *et al.* (2006) *Bone Marrow Transplant.* 37 (Suppl. 1): 67.
13. Marabelle *et al.* (2011) *Pediatr. Blood Cancer* 56: 134–142.
14. Ballova *et al.* (2008) *Neoplasma* 55: 428–436.
15. Atkins *et al.* (2012) *Biol. Blood Marrow Transplant.* 18 (Suppl. 1): S177–183.
16. Vonk *et al.* (2008) *Ann. Rheum. Dis.* 67: 98–104.
17. Alexander *et al.* (2009) *Blood* 113: 214–223.
18. Kreisel *et al.* (2003) *Bone Marrow Transplant.* 32: 337–340.
19. Fernández (2009): *British Journal of Haematology* 147: 161–176.
20. Bautista *et al.* (2009): *Bone Marrow Transplant.* 43: 365–373.
21. Lindemans *et al.* (2012) *BBMT* 18 (Suppl. 2): S214.
22. Liu *et al.* (2011): *Blood* 118: 6438–6445.
23. Schumm *et al.* (2006) *Cytotherapy* 8: 465–472.
24. Gonzalez-Vicent *et al.* (2010) *J. Pediatr. Hematol. Oncol.* 32: e85–90.
25. D’Asaro *et al.* (2010) *J. Immunol.* 184: 3260–3268.
26. Kordelas *et al.* (2008) *Blood* 112: Abstract 2223.
27. Godder *et al.* (2007) *Bone Marrow Transplant.* 39: 751–757.
28. Knight *et al.* (2010) *Blood* 116: 2164–2172.
29. Schumm *et al.* (2011) *Bone Marrow Transplant.* 46 (Suppl. 1): P1093.
30. Handgretinger *et al.* (2011) *Blood* 118: Abstract 1005.
31. Anderson *et al.* (2003) *J. Clin. Invest.* 112: 101–108.
32. Handgretinger *et al.* (2007) *Ann. N. Y. Acad. Sci.* 1106: 279–289.
33. Lang *et al.* (2005) *Klin. Padiatr.* 217: 334–348.
34. Lang *et al.* (2011) *Bone Marrow Transplant.* 46 (Suppl. 1): P559.
35. Handgretinger *et al.* (2008) *Cytotherapy* 10: 443–451.
36. Lang *et al.* (2008) *Bone Marrow Transplant.* 42 (Suppl. 2): S54–S59.
37. Bethge *et al.* (2008) *Blood Cells Mol. Dis.* 40: 13–19.
38. Federmann *et al.* (2009) *Bone Marrow Transplant.* 43 (Suppl. 1): S66.
39. Federmann *et al.* (2011) *Leukemia* 25: 121–129.
40. Bader *et al.* (2011) *Best Pract. Res. Clin. Hematol.* 24: 331–337.
41. The EBMT Handbook 6th Edition, Haematopoietic Stem Cell Transplantation, 2012, ISBN 978-88-89620-15-1.



Miltenyi Biotec

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC (“human tissues and cells”), or the Directive 2002/98/EC (“human blood and blood components”) – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or FDA approval. CliniMACS GMP MicroBeads are for research use and *ex vivo* cell processing only. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.